Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Said

Showing results (61-70 of 126) with videos related to

Pageof 13
Sort By:
Journal of Hematology & Oncology|November 28, 2025
Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
BJU International|January 7, 2012
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinomaBrian Shuch, Gennady Bratslavsky, Joanna Shih, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 26, 2009
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomyTobias Klatte, David B Seligson, Jeffrey LaRochelle, et al.
Journal of Hematology & Oncology|November 15, 2017
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinomaTobias Klatte, Allan J Pantuck, Jonathan W Said, et al.
The Journal of Urology|February 24, 2009
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classificationTobias Klatte, Jonathan W Said, Michela de Martino, et al.
Leukemia & Lymphoma|January 21, 2012
Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphomaNils H Thoennissen, Gabriela B Thoennissen, Sam Abbassi, et al.
The Journal of Urology|November 16, 2010
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell featuresTobias Klatte, Jonathan W Said, David B Seligson, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomasSven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Molecular Cancer Therapeutics|October 31, 2013
Off-target effects of c-MET inhibitors on thyroid cancer cellsYan Zhou, Conghui Zhao, Sigal Gery, et al.
Pageof 13

Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Journal of Hematology & Oncology|November 28, 2025
Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
BJU International|January 7, 2012
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinomaBrian Shuch, Gennady Bratslavsky, Joanna Shih, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 26, 2009
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomyTobias Klatte, David B Seligson, Jeffrey LaRochelle, et al.
Journal of Hematology & Oncology|November 15, 2017
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinomaTobias Klatte, Allan J Pantuck, Jonathan W Said, et al.
The Journal of Urology|February 24, 2009
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classificationTobias Klatte, Jonathan W Said, Michela de Martino, et al.
Leukemia & Lymphoma|January 21, 2012
Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphomaNils H Thoennissen, Gabriela B Thoennissen, Sam Abbassi, et al.
The Journal of Urology|November 16, 2010
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell featuresTobias Klatte, Jonathan W Said, David B Seligson, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomasSven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Molecular Cancer Therapeutics|October 31, 2013
Off-target effects of c-MET inhibitors on thyroid cancer cellsYan Zhou, Conghui Zhao, Sigal Gery, et al.
Pageof 13